Conjunctival benign reactive lymphoid hyperplasia associated with myopic scleral thinning

University of Queensland, Brisbane, Queensland, Australia
Clinical and Experimental Ophthalmology (Impact Factor: 1.95). 03/2005; 33(1):73-5. DOI: 10.1111/j.1442-9071.2004.00947.x
Source: PubMed

ABSTRACT Known causes of conjunctival salmon patches include lymphoma, amyloidosis, sarcoidosis, leukaemia and benign reactive lymphoid hyperplasia. The aetiology of benign reactive lymphoid hyperplasia is thought to be a localized reactive change induced by an irritative or antigenic stimulus. The case of benign reactive lymphoid hyperplasia reported herein occurred in a myopic patient with extremely thin sclera. The authors' hypothesis is that choroidal antigens are able to perfuse through thin sclera and act as chronic irritants to the overlying conjunctiva resulting in a lymphoid response and subsequent salmon patch formation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a 70-year-old man with a salmon patch conjunctival mass diagnosed as multiple myeloma. Case report. Surgical biopsies of the salmon patch conjunctival mass and bone marrow, as well as hematologic workup for multiple myeloma were performed. Conjunctival biopsy revealed heavy myeloma cells with eccentric nuclei and basophilic cytoplasm infiltrate in the conjunctival stroma. Bone marrow biopsy and aspirate showed interstitial infiltrated by myeloma cells, which stained monoclonally for immunoglobulin G (IgG)-kappa light chains. Hematologic tests confirmed the diagnosis of multiple myeloma. Multiple myeloma is one of the causes of a salmon patch conjunctival lesion and may be included in the differential diagnosis.
    American Journal of Ophthalmology 06/2006; 141(5):948-9. DOI:10.1016/j.ajo.2005.11.059 · 4.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine if there is an increased rate of postoperative bacterial endophthalmitis after resident-performed cataract extraction relative to the reported rates of experienced surgeons. Retrospective, observational case series. The operative reports of the resident-performed cataract surgeries at San Francisco General Hospital between 1983 and 2002 were reviewed. Cases of culture-positive bacterial endophthalmitis and vitreous loss were identified. Between 1983 and 2002, three cases (0.11%) of culture-positive bacterial endophthalmitis occurred after 2718 resident-performed cataract extractions. The overall vitreous loss rate was 6.7%. Two endophthalmitis cases were acute (Staphylococcus epidermidis, Streptococcus viridans), presenting within five days of surgeries complicated by vitreous loss, and one case was delayed-onset (Corynebacterium species) after Nd:YAG posterior capsulotomy after uncomplicated cataract extraction. Despite higher rates of vitreous loss, the rate of endophthalmitis following resident-performed cataract surgery remains comparable with the rates of more experienced surgeons.
    American Journal of Ophthalmology 06/2006; 141(5):949-51. DOI:10.1016/j.ajo.2005.11.055 · 4.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m2, intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.
    Mayo Clinic Proceedings 07/2007; 82(6):692-9. DOI:10.4065/82.6.692 · 5.81 Impact Factor
Show more